I’m not sure the results are confusing at all. Or as difficult as Roger makes out.
SRX stated categorically on a number of occasions that if the primary end-point of PFS was not met then first line SIRT has a weak case and would remain a salvage therapy.
The primary outcome was not met ... full stop.
Next there are 7 secondary outcomes. SRX announce a statistically sig improvement on one of these outcomes - PFS in the liver.
So what? It is simply a surrogate for OS. In the 2010 study SIRSPHERES failed to beat placebo on OS. If OS were showing a positive trend you can bet SRX would have mentioned it.
Plan A was to present only the top line overall PFS results in this announcement. Plan B emerges from the failure. But in the absence of positive OS data it is doomed to fail.
The truth is just as the company stated before the results.
- Forums
- ASX - By Stock
- SRX
- Roger Montgomery on Sirtex
Roger Montgomery on Sirtex, page-79
-
- There are more pages in this discussion • 87 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SRX (ASX) to my watchlist
(20min delay)
|
|||||
Last
17.8¢ |
Change
-0.003(1.39%) |
Mkt cap ! $75.34M |
Open | High | Low | Value | Volume |
17.8¢ | 17.8¢ | 17.5¢ | $8.638K | 48.69K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 11236354 | 17.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
18.0¢ | 1327703 | 33 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
8 | 11236354 | 0.175 |
1 | 164705 | 0.170 |
1 | 18187 | 0.165 |
1 | 2577 | 0.097 |
1 | 4000 | 0.075 |
Price($) | Vol. | No. |
---|---|---|
0.180 | 1327703 | 33 |
0.185 | 5000 | 1 |
0.190 | 315669 | 6 |
0.195 | 20478 | 2 |
0.200 | 427416 | 7 |
Last trade - 15.52pm 09/09/2024 (20 minute delay) ? |
Featured News
SRX (ASX) Chart |